quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:01:13·55d
INSIDERFiling
Caribou Biosciences Inc. logo

Chief Technology Officer Kelly Timothy P sold $12,020 worth of shares (6,228 units at $1.93), decreasing direct ownership by 8% to 73,125 units (SEC Form 4)

CRBU· Caribou Biosciences Inc.
Health Care
Original source

Companies

  • CRBU
    Caribou Biosciences Inc.
    Health Care

Recent analyst ratings

  • Jun 3UpdateEvercore ISI$3.00
  • Nov 8UpdateCantor Fitzgerald-
  • Oct 31UpdateEvercore ISI$13.00
  • Jul 11UpdateTruist$23.00
  • Feb 18UpdateRBC Capital$22.00
  • Feb 14UpdateBrookline Capital$19.00

Related

  • SEC13d
    SEC Form PRE 14A filed by Caribou Biosciences Inc.
  • SEC24d
    Caribou Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR24d
    Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
  • SEC49d
    SEC Form S-8 filed by Caribou Biosciences Inc.
  • SEC49d
    SEC Form 10-K filed by Caribou Biosciences Inc.
  • SEC49d
    Caribou Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR49d
    Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
  • SEC57d
    SEC Form 144 filed by Caribou Biosciences Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022